Discovery Laboratories has announced that the US Patent and Trademark Office (USPTO) has issued the company a new patent titled “Ventilation Circuit Adaptor and Proximal Aerosol Delivery System” (Patent No. 8,701,658) and Notices of Allowance for two patents titled “Lyophilization of Synthetic Liposomal Pulmonary Surfactant” (application nos.14/091,608 and 14/091,712).
The company is developing the lyophilized KL4 surfactant for its Aerosurf system for the treatment of respiratory distress syndrome in premature infants. It submitted an IND for the product in October 2013.
The newly patented aerosol airway connectors for the system are disposable and, the company says, “intended to simplify the delivery of inhaled therapies including aerosolized KL4 surfactant to infants requiring ventilatory support.”
Discovery Labs CEO John G. Cooper commented, “Our goal at Discovery Labs is to build a company focused on addressing the needs of critical care patients suffering from respiratory diseases, beginning with respiratory distress syndrome in premature infants. These important new patents are indicative of our efforts to protect the long-term commercial potential of our platform technology. We initially are utilizing lyophilized KL4 surfactant for our Aerosurf development program. And while providing new technologies for these premature infants is our top priority, our longer term goal is to leverage our technology into developing products for other potential indications for which our proprietary KL4 surfactant could be of use.”
Read the Discovery Labs press release.
